TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
TuHURA Biosciences Inc HURA.OQ reported a quarterly adjusted loss of 14 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -21 cents. The mean expectation of five analysts for the quarter was for a loss of 14 cents per share. Wall Street expected results to range from -21 cents to -12 cents per share.
Reported revenue was zero; analysts expected zero.
TuHURA Biosciences Inc's reported EPS for the quarter was a loss of 14 cents.
The company reported a quarterly loss of $9.22 million.
TuHURA Biosciences Inc shares had fallen by 1.7% this quarter and gained 204.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 26.1% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for TuHURA Biosciences Inc is $8.00, about 71.3% above its last closing price of $2.30
This summary was machine generated from LSEG data August 14 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.14 | -0.14 | Met |
Mar. 31 2026 | -0.11 | -0.13 | Missed |
Dec. 31 2025 | -0.13 | -0.17 | Missed |
Sep. 30 2025 | -0.15 | -0.13 | Beat |
Recent news on TuHURA Biosciences
See all newsBrief: Tuhura Biosciences Receives Key U.S. Patent For Its Groundbreaking Delta Opioid Receptor Antibody Drug Conjugate Technology
TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update
TuHURA Biosciences Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.